Edgewise Therapeutics (EWTX) Shares Outstanding (2020 - 2026)

Edgewise Therapeutics has disclosed Shares Outstanding across 7 years of filings, most recently posting $107.5 million for Q1 2026.

• Shares Outstanding for Q1 2026 came in at $107.5 million, up 12.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $107.5 million (up 12.89% YoY), and the FY2025 annual result was $106.2 million, up 12.03% from the prior year.
• Shares Outstanding came in at $107.5 million for Q1 2026 at Edgewise Therapeutics, up from $106.2 million in the prior quarter.
• In the past five years, Shares Outstanding ranged from a high of $107.5 million in Q1 2026 to a low of $49.6 million in Q1 2022.
• The 5-year median for Shares Outstanding is $93.3 million (2024), against an average of $81.3 million.
• Across the five-year window, Shares Outstanding advanced 0.4% in 2023 and soared 48.77% in 2024, its largest moves.
• Edgewise Therapeutics' Shares Outstanding stood at $63.3 million in 2022, then gained by 11.38% to $70.5 million in 2023, then jumped by 34.61% to $94.8 million in 2024, then advanced by 12.03% to $106.2 million in 2025, then climbed by 1.16% to $107.5 million in 2026.
• The last three Shares Outstanding figures came in at $107.5 million (Q1 2026), $106.2 million (Q4 2025), and $105.8 million (Q3 2025), per Business Quant data.